This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Evaluation of the Efficacy of Bio-K+ Cl-1285® In the Nasal Decolonization of Methicillin Resistant Staphylococcus Aureus (MRSA) Carrier Patients (MRSA)

This study has suspended participant recruitment.
(Unable to recruit patients to continue on with the study.)
Centre Hospitalier Pierre-Le Gardeur
Information provided by (Responsible Party):
Bio-K Plus International Inc. Identifier:
First received: January 15, 2009
Last updated: January 14, 2016
Last verified: January 2016

Trial Objectives:

Primary objective:

  • To evaluate the efficacy of Bio-K+CL1285® in patients with Methicillin-Resistant S. aureus (MRSA) nasal colonization by comparing the MRSA decolonization following either Bio-K+CL1285® or placebo treatment.

Secondary objective:

  • To evaluate the safety profile of Bio-K+CL1285®.

Condition Intervention Phase
MRSA Colonization Dietary Supplement: Bio-K+ CL1285 Dietary Supplement: Placebo Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Single Center, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy of Bio-K+ Cl-1285® In the Nasal Decolonization of Methicillin Resistant Staphylococcus Aureus (MRSA) Carrier Patients

Resource links provided by NLM:

Further study details as provided by Bio-K Plus International Inc.:

Primary Outcome Measures:
  • Frequency of subjects with MRSA decolonization [ Time Frame: 21 days ]

Secondary Outcome Measures:
  • To evaluate the secondary effects (incidence rate of non-serious ans serious adverse events)associated to the administration of the study product [ Time Frame: 21 days ]

Estimated Enrollment: 146
Study Start Date: January 2010
Estimated Primary Completion Date: July 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Bio-K+ CL1285 contains 50 billion of live bacteria
Dietary Supplement: Bio-K+ CL1285
2 capsules per day before breakfast
Other Name: Bio-K+ CL1285(R) Extra Strength
Placebo Comparator: 2
placebo devoid of bacteria
Dietary Supplement: Placebo
2 capsules per day before breakfast

Detailed Description:

Study Design:

Double-blind, randomized (1:1 randomization), placebo-controlled, single center Canadian study.

Patients will be randomly assigned to one of the two study products. A randomization schedule will be generated by the sponsor for each participating centre. This schedule will link patient identification numbers to one of the two study products allocated at random. The schedule will be prepared on a 1:1 randomization ratio.

The study products will be labelled with the patient identification number. Patients have to be randomized in the order in which they qualify from the screening phase for inclusion in the study.

Patients withdrawn from the study retain their patient number if already given. New patients must always be allotted a new identification number (PIN).

Study Duration:

The duration of patient participation in the study will be between 22 and 23 days. The overall duration of the study is expected to be approximately 10 months; with subject recruitment proposed to start in March 2009, the last follow-up visit is expected in May 2010. The actual overall study duration or subject recruitment period may vary.

Number of Sites (inside and outside of Canada):

One center in the province of Quebec will be involved in the study.


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or female patients having ≥18 years of age
  • Women of child bearing capacity who are not pregnant at the moment of screening (Pregnancy test done on-site) and agree to use an acceptable form of birth control for the duration of the study (e.g. condom, oral contraceptives, etc.) are allowed to participate.
  • Patients must have nasal MRSA colonization confirmed with MRSA positive culture as assessed during the screening visit without any clinical signs or symptoms of infection.
  • Laboratory test results within the normal ranges.
  • Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

  • Patients treated for nasal MRSA decolonization in the last 6 months;
  • Current infection with MRSA;
  • Ongoing or active infection;
  • Daily probiotic/ fermented milk or Yogurt use;
  • Known to have shown a previous reaction, including anaphylaxis, to any substance in composition of the study agent (capsules);
  • Ongoing or recent use of antibiotics in the 30 days prior to the study agent administration;
  • Pregnancy, breastfeeding;
  • Regular use of nasal agents;
  • Uncontrolled intercurrent illness, including situations that would limit compliance with study requirements;
  • Patients with open wounds
  • Immunosuppressive therapy or any health condition causing inmunosuppression (Including Haematological malignancies, AIDS);
  • Ostomized patients, parenteral nutrition users;
  • Patients with current vascular access (catheter) or planned to have installed a vascular access (catheter) or any prosthesis during the study period.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00941356

Canada, Quebec
Pierre Le Gardeur Hospital
Terrebonne, Quebec, Canada, J6V 2H2
Sponsors and Collaborators
Bio-K Plus International Inc.
Centre Hospitalier Pierre-Le Gardeur
Principal Investigator: Dr Pierre-Jean PM Maziade, MD Pierre Le Gardeur Hospital
  More Information

Responsible Party: Bio-K Plus International Inc. Identifier: NCT00941356     History of Changes
Other Study ID Numbers: CL1285-MRSA-M03
Study First Received: January 15, 2009
Last Updated: January 14, 2016

Keywords provided by Bio-K Plus International Inc.:
MRSA nasal colonisation

Additional relevant MeSH terms:
Staphylococcal Infections
Gram-Positive Bacterial Infections
Bacterial Infections
Anti-Bacterial Agents
Anti-Infective Agents processed this record on September 21, 2017